Recent ECDC data show that despite progress in prevention and control efforts, the hepatitis B and hepatitis C viruses (HBV and HCV) continue to pose significant public health challenges in the European Union and European Economic Area (EU/EEA).
Since late February 2023 and up until 30 March 2023, 87 cases of botulism linked to intragastric injection of the botulinum neurotoxin (BoNT) have been reported.
Since late February 2023 and as of 10 March 2023, 67 cases of botulism linked to intragastric injection of the botulism neurotoxin (BoNT) have been reported in Germany (12), Austria (1), Switzerland (1) and Türkiye (53).
A number of European countries (including Ireland, France, the Netherlands, Sweden and the United Kingdom) indicate an increase seen during 2022, particularly since September 2022, in the number of cases of invasive Group A Streptococcus (iGAS) disease among children less than ten years of age.
ECDC provides support to EU/EEA countries in monitoring their progress towards the hepatitis elimination targets and has just published a report based on the second data collection.